Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 1

Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy

Authors Colombo G, Caruggi M, Ottolini C, Maggioni AP

Published 8 February 2008 Volume 2008:4(1) Pages 223—234

DOI https://doi.org/10.2147/VHRM.S2446

Giorgio L Colombo1, Mauro Caruggi2, Chiara Ottolini3, Aldo P Maggioni4

1S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy; 2Università degli Studi dell’Insubria, Varese, Italy;3Azienda Ospedaliera di Busto Arsizio, Varese, Italy; 4ANMCO Research Center, Italian Association of Hospital Cardiologists, Firenze, Italy (CHARM Steering Committee Member)

Abstract: Chronic heart failure (HF) is a major cause of morbidity and mortality particularly in the elderly and a growing healthcare burden in Italy. The objective was to assess the cost-effectiveness of candesartan cilexetil, an angiotensin II type 1 receptor blocker (ARB) for the treatment of HF. A pre-specified economic evaluation was conducted on resource utilization (cardiovascular drug treatment, cardiovascular and non-cardiovascular hospital admission, cardiovascular procedures/operations) prospectively collected alongside the CHARM program, a series of parallel randomized clinical trials comparing candesartan with placebo (standard therapy) in patients with NYHA Class II-IV HF: CHARM-Alternative (LVEF ≤40% patients not receiving ACE inhibitors because of previous intolerance); CHARM-Added (LVEF ≤40% patients currently receiving ACE inhibitors); or CHARM-Preserved (LVEF ≥40% patients). The primary outcome for the component trials was the composite of cardiovascular death or worsening hospital admission for HF and of the overall program all-cause mortality. Adjunctive treatment with candesartan in CHARM-Alternative and CHARM-Added led to clinical benefits and to either cost-savings or a small additional cost, depending on the trial. The less certain clinical benefit in CHARM-Preserved was obtained at modest extra cost. The incremental cost-effectiveness ratios (ICERs) were estimated to range from €713 per life year gained for CHARM-Alternative to dominant for CHARM-Added and the pooled reduced LVEF trials.

Keywords: candesartan, heart failure, cost-effectiveness analysis, cost-consequence analysis, CHARM, Italy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers

Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G

Therapeutics and Clinical Risk Management 2015, 11:1603-1612

Published Date: 19 October 2015

Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation

Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C

Patient Related Outcome Measures 2015, 6:53-60

Published Date: 17 February 2015

Economic and outcomes consequences of TachoSil®: a systematic review

Colombo GL, Bettoni D, Di Matteo S, Grumi C, Molon C, Spinelli D, Mauro G, Tarozzo A, Bruno GM

Vascular Health and Risk Management 2014, 10:569-576

Published Date: 10 September 2014

Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines

Colombo GL, Matteo SD, Antinori A, Medaglia M, Murachelli S, Rizzardini G

ClinicoEconomics and Outcomes Research 2013, 5:489-496

Published Date: 3 October 2013

A cost-of-illness study of spina bifida in Italy

Colombo GL, Di Matteo S, Vinci M, Gatti C, Pascali MP, De Gennaro M, Macrellino E, Mosiello G, Redaelli T, Schioppa F, Dieci C

ClinicoEconomics and Outcomes Research 2013, 5:309-316

Published Date: 2 July 2013

Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy

Ruggeri I, Bragato D, Colombo GL, Valla E, Di Matteo S

ClinicoEconomics and Outcomes Research 2012, 4:375-382

Published Date: 5 December 2012

Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy

Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL

Therapeutics and Clinical Risk Management 2012, 8:377-384

Published Date: 17 September 2012

Antidiabetic therapy in real practice: indicators for adherence and treatment cost

Colombo GL, Rossi E, De Rosa M, Benedetto D, Gaddi AV

Patient Preference and Adherence 2012, 6:653-661

Published Date: 14 September 2012

Burden of Crohn’s disease: economics and quality of life aspects in Italy

Benedini V, Caporaso N, Corazza GR, Rossi Z, Fornaciari G, Cottone M, Frosini G, Caruggi M, Ottolini C, Colombo GL

ClinicoEconomics and Outcomes Research 2012, 4:209-218

Published Date: 24 July 2012

Cost-effectiveness analysis of initial HIV treatment under Italian guidelines

Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P

ClinicoEconomics and Outcomes Research 2011, 3:197-205

Published Date: 31 October 2011

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

Giorgio L Colombo, Sergio Di Matteo, Maria Elisa Mancuso, et al

ClinicoEconomics and Outcomes Research 2011, 3:55-61

Published Date: 14 March 2011

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

Giorgio L Colombo, Giovanni B Gaeta, Mauro Viganò, et al

ClinicoEconomics and Outcomes Research 2011, 3:37-46

Published Date: 15 February 2011

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy

Giorgio L Colombo, Sergio Di Matteo, Ketty Peris, Maria Concetta Fargnoli, et al.

ClinicoEconomics and Outcomes Research 2009, 1:53-59

Published Date: 15 October 2009

Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis

V Nicosia, Giorgio Colombo, M Consentino, S Di Matteo, F Mika, et al

Therapeutics and Clinical Risk Management 2008, 4:1105-1110

Published Date: 10 October 2008

Moderate and severe plaque psoriasis: cost-of-illness study in Italy

GL Colombo, GF Altomare, K Peris, P Martini, G Quarta

Therapeutics and Clinical Risk Management 2008, 4:559-568

Published Date: 11 April 2008

Readers of this article also read:

Biomimetic component coating on 3D scaffolds using high bioactivity of mesoporous bioactive ceramics

Yun HS, Kim SH, Khang DW, Choi JI, Kim HH, Kang MJ

International Journal of Nanomedicine 2011, 6:2521-2531

Published Date: 21 October 2011

Sleep restriction increases white blood cells, mainly neutrophil count, in young healthy men: A pilot study

Karim Zouaoui Boudjeltia, Brice Faraut, Patricia Stenuit, Maria José Esposito, Michal Dyzma, et al

Vascular Health and Risk Management 2008, 4:1467-1470

Published Date: 5 December 2008

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

Ehud Rechtman, Alon Harris, Hanna J Garzozi, Thomas A Ciulla

Clinical Ophthalmology 2007, 1:383-391

Published Date: 15 February 2008

A hazardous finding of a rare anomalous left main coronary artery in a patient with a secundum atrial septal defect

Michael Emery, Waqas Ghumman, Shawn Teague, Jo Mahenthiran

Vascular Health and Risk Management 2008, 4:259-262

Published Date: 8 February 2008

Gadofosveset-enhanced magnetic resonance angiography

Mathias Goyen

Vascular Health and Risk Management 2008, 4:1-9

Published Date: 8 February 2008

Adherence treatment factors in hypertensive African American women

Marie N Fongwa, Lorraines S Evangelista, Ron D Hays, David S Martins, David Elashoff, et al

Vascular Health and Risk Management 2008, 4:157-166

Published Date: 8 February 2008

Bisoprolol in the treatment of chronic heart failure

Pascal de Groote, Pierre-Vladimir Ennezat, Fréderic Mouquet

Vascular Health and Risk Management 2007, 3:431-439

Published Date: 15 September 2007

Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2

Allen J Taylor, Daming Zhu, Lance E Sullenberger, Hyun J Lee, Jeannie K Lee, Karen A Grace

Vascular Health and Risk Management 2007, 3:159-164

Published Date: 15 March 2007